Home » Stocks » ADAG

Adagene, Inc. (ADAG)

Stock Price: $13.53 USD -0.20 (-1.46%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 572.69M
Revenue (ttm) 700,913
Net Income (ttm) -42.65M
Shares Out 42.33M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $13.53
Previous Close $13.73
Change ($) -0.20
Change (%) -1.46%
Day's Open 13.67
Day's Range 13.50 - 13.78
Day's Volume 4,896
52-Week Range 11.11 - 31.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming t...

2 weeks ago - GlobeNewsWire

-Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement

3 weeks ago - GlobeNewsWire

SAN FRANCISCO and SUZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the dis...

2 months ago - GlobeNewsWire

- Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds- -Reported clinical data for anti-CD137 and two anti-CTLA-4 programs- -Advanced five discovery pro...

2 months ago - GlobeNewsWire

-NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial-  -Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism- -Poised for global ex...

2 months ago - GlobeNewsWire

SAFEbody technology enables precision masking of antibodies for enhanced safety SAFEbody technology enables precision masking of antibodies for enhanced safety

2 months ago - GlobeNewsWire

SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the disco...

4 months ago - GlobeNewsWire

SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming t...

4 months ago - GlobeNewsWire

Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utilize Adagene’s SAFEbody™ technology platform...

4 months ago - Business Wire

Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, filed on Tuesday with the SEC to raise up to $125 million in an initial public offering.

4 months ago - NASDAQ

Adagene, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

Dragonfly’s partnership with AbbVie is beginning to bear fruit. AbbVie has selected its first NK cell engager-based immunotherapy as part of the deal, triggering an undisclosed opt-in payment, the compa...

5 months ago - Endpoints News

Yields potential first-ever antibodies targeting human endogenous retrovirus associated with kidney cancer.

5 months ago - Contract Pharma

About ADAG

Adagene is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. We have developed our proprietary AI-Powered DPL platform to explore the dynamic conformational diversity of protein sequences, and the flexible binding sites of antibody sequences in particular, as a new paradigm for antibody drug discovery. Our DPL platform combines artificial intelligence, or AI, algorithms and ever-increasing big data in antibody sequence, structure, b... [Read more...]

Industry
Biotechnology
IPO Date
Feb 9, 2021
CEO
Peter (Peizhi) Luo, Ph.D.
Employees
198
Stock Exchange
NASDAQ
Ticker Symbol
ADAG
Full Company Profile

Financial Performance

In 2020, Adagene's revenue was $700,913, an increase of 46.02% compared to the previous year's $480,000. Losses were -$42.40 million, 158.0% more than in 2019.

Financial Statements